[go: up one dir, main page]

SI3110442T1 - Modificirani meningokokni fHbp polipeptidi - Google Patents

Modificirani meningokokni fHbp polipeptidi

Info

Publication number
SI3110442T1
SI3110442T1 SI201531437T SI201531437T SI3110442T1 SI 3110442 T1 SI3110442 T1 SI 3110442T1 SI 201531437 T SI201531437 T SI 201531437T SI 201531437 T SI201531437 T SI 201531437T SI 3110442 T1 SI3110442 T1 SI 3110442T1
Authority
SI
Slovenia
Prior art keywords
meningococcal fhbp
fhbp polypeptides
modified meningococcal
modified
polypeptides
Prior art date
Application number
SI201531437T
Other languages
English (en)
Inventor
Matthew Bottomley
Enrico Malito
Manuele Martinelli
Maria Scarselli
Original Assignee
Glaxosmithkline Biologicals S.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Biologicals S.A. filed Critical Glaxosmithkline Biologicals S.A.
Publication of SI3110442T1 publication Critical patent/SI3110442T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/095—Neisseria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/22—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Neisseriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/10—Plasmid DNA
    • C12N2800/101—Plasmid DNA for bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
SI201531437T 2014-02-28 2015-02-27 Modificirani meningokokni fHbp polipeptidi SI3110442T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP14157399 2014-02-28
EP14177566 2014-07-17
PCT/EP2015/054174 WO2015128480A1 (en) 2014-02-28 2015-02-27 Modified meningococcal fhbp polypeptides
EP15707351.1A EP3110442B1 (en) 2014-02-28 2015-02-27 Modified meningococcal fhbp polypeptides

Publications (1)

Publication Number Publication Date
SI3110442T1 true SI3110442T1 (sl) 2021-01-29

Family

ID=52596977

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201531437T SI3110442T1 (sl) 2014-02-28 2015-02-27 Modificirani meningokokni fHbp polipeptidi

Country Status (23)

Country Link
US (4) US10392424B2 (sl)
EP (2) EP3110442B1 (sl)
JP (3) JP6786394B2 (sl)
KR (2) KR20160127104A (sl)
CN (1) CN106661092B (sl)
AU (2) AU2015222121B2 (sl)
CA (1) CA2940447C (sl)
CY (1) CY1123622T1 (sl)
DK (1) DK3110442T3 (sl)
EA (1) EA034954B1 (sl)
ES (1) ES2841378T3 (sl)
HR (1) HRP20202080T1 (sl)
HU (1) HUE052293T2 (sl)
IL (1) IL247125B (sl)
LT (1) LT3110442T (sl)
MX (2) MX373277B (sl)
PL (1) PL3110442T3 (sl)
RS (1) RS61246B1 (sl)
SG (2) SG10201907875TA (sl)
SI (1) SI3110442T1 (sl)
SM (1) SMT202000704T1 (sl)
WO (1) WO2015128480A1 (sl)
ZA (1) ZA201605534B (sl)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201907875TA (en) 2014-02-28 2019-09-27 Glaxosmithkline Biologicals Sa Modified meningococcal fhbp polypeptides
CN106659776A (zh) 2014-07-17 2017-05-10 葛兰素史密丝克莱恩生物有限公司 脑膜炎球菌疫苗
AR102324A1 (es) 2014-07-17 2017-02-22 Glaxosmithkline Biologicals Sa Polipéptidos fhbp (proteína de unión al factor h) meningocócicos modificados
ES2922554T3 (es) 2014-07-23 2022-09-16 Childrens Hospital & Res Center At Oakland Variantes de proteínas de unión al factor H y métodos de uso de las mismas
GB201614687D0 (en) * 2016-08-31 2016-10-12 Univ Oxford Innovation Ltd fHbp scaffold
IL267733B2 (en) * 2017-01-31 2023-10-01 Pfizer Neisseria meningitidis compositions and methods thereof
EP3607967A1 (en) 2018-08-09 2020-02-12 GlaxoSmithKline Biologicals S.A. Modified meningococcal fhbp polypeptides
WO2020182635A1 (en) 2019-03-08 2020-09-17 Glaxosmithkline Biologicals Sa Carbocyclic derivatives and conjugated derivatives thereof, and their use in vaccines
GB202013262D0 (en) 2020-08-25 2020-10-07 Glaxosmithkline Biologicals Sa Vaccine Composition
TW202245836A (zh) 2021-02-19 2022-12-01 美商賽諾菲巴斯德公司 重組ｂ型腦膜炎球菌疫苗
GB202115151D0 (en) 2021-10-21 2021-12-08 Glaxosmithkline Biologicals Sa Methods
GB202208093D0 (en) 2022-06-01 2022-07-13 Glaxosmithkline Biologicals Sa Immunogenic composition
GB202208089D0 (en) 2022-06-01 2022-07-13 Glaxosmithkline Biologicals Sa Immunogenic composition
TW202423477A (zh) 2022-08-03 2024-06-16 美商賽諾菲巴斯德公司 針對腦膜炎奈瑟氏菌b的含佐劑免疫原性組成物

Family Cites Families (92)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4057685A (en) 1972-02-02 1977-11-08 Abbott Laboratories Chemically modified endotoxin immunizing agent
DE2848965A1 (de) 1978-11-11 1980-05-22 Behringwerke Ag Verfahren zur herstellung von membranproteinen aus neisseria meningitidis und diese enthaltende vaccine
US4356170A (en) 1981-05-27 1982-10-26 Canadian Patents & Development Ltd. Immunogenic polysaccharide-protein conjugates
US4673574A (en) 1981-08-31 1987-06-16 Anderson Porter W Immunogenic conjugates
US4459286A (en) 1983-01-31 1984-07-10 Merck & Co., Inc. Coupled H. influenzae type B vaccine
US4663160A (en) 1983-03-14 1987-05-05 Miles Laboratories, Inc. Vaccines for gram-negative bacteria
US4761283A (en) 1983-07-05 1988-08-02 The University Of Rochester Immunogenic conjugates
US4695624A (en) 1984-05-10 1987-09-22 Merck & Co., Inc. Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency
US4882317A (en) 1984-05-10 1989-11-21 Merck & Co., Inc. Covalently-modified bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers and methods of preparing such polysaccharides and conjugataes and of confirming covalency
US4808700A (en) 1984-07-09 1989-02-28 Praxis Biologics, Inc. Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers
IT1187753B (it) 1985-07-05 1987-12-23 Sclavo Spa Coniugati glicoproteici ad attivita' immunogenica trivalente
JPH01125328A (ja) 1987-07-30 1989-05-17 Centro Natl De Biopreparados 髄膜炎菌ワクチン
NL8802046A (nl) 1988-08-18 1990-03-16 Gen Electric Polymeermengsel met polyester en alkaansulfonaat, daaruit gevormde voorwerpen.
DE3841091A1 (de) 1988-12-07 1990-06-13 Behringwerke Ag Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung
JP3436756B2 (ja) 1988-12-19 2003-08-18 アメリカン・サイアナミド・カンパニー 髄膜炎菌のクラスｉの外膜タンパク質のワクチン
CA2006700A1 (en) 1989-01-17 1990-07-17 Antonello Pessi Synthetic peptides and their use as universal carriers for the preparation of immunogenic conjugates suitable for the development of synthetic vaccines
EP0482068A1 (en) 1989-07-14 1992-04-29 American Cyanamid Company Cytokine and hormone carriers for conjugate vaccines
IT1237764B (it) 1989-11-10 1993-06-17 Eniricerche Spa Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici.
SE466259B (sv) 1990-05-31 1992-01-20 Arne Forsgren Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal
ATE128628T1 (de) 1990-08-13 1995-10-15 American Cyanamid Co Faser-hemagglutinin von bordetella pertussis als träger für konjugierten impfstoff.
IT1262896B (it) 1992-03-06 1996-07-22 Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini.
IL102687A (en) 1992-07-30 1997-06-10 Yeda Res & Dev Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
NL9201716A (nl) 1992-10-02 1994-05-02 Nederlanden Staat Buitenmembraanvesikel dat voorzien is van een groep polypeptiden welke ten minste de immuunwerking van aan membraan gebonden buitenmembraaneiwitten (OMP's) hebben, werkwijze ter bereiding ervan alsmede een vaccin dat een dergelijk buitenmembraanvesikel omvat.
CA2171942C (en) 1993-09-22 2010-12-14 Andrew Lees Method of activating soluble carbohydrate using novel cyanylating reagents for the production of immunogenic constructs
IL117483A (en) 1995-03-17 2008-03-20 Bernard Brodeur MENINGITIDIS NEISSERIA shell protein is resistant to proteinase K.
US6180111B1 (en) 1995-05-18 2001-01-30 University Of Maryland Vaccine delivery system
US6558677B2 (en) 1996-10-15 2003-05-06 Wendell D. Zollinger Vaccine against gram negative bacteria
GB9711964D0 (en) 1997-06-09 1997-08-06 Medical Res Council Live attenuated vaccines
GB9713156D0 (en) 1997-06-20 1997-08-27 Microbiological Res Authority Vaccines
ATE384130T1 (de) 1997-08-21 2008-02-15 Nederlanden Staat Neue mutanten der gram-negativen mukosalen bakterien und ihre verwendung als impfstoffe
US6747137B1 (en) * 1998-02-13 2004-06-08 Genome Therapeutics Corporation Nucleic acid sequences relating to Candida albicans for diagnostics and therapeutics
US6551795B1 (en) * 1998-02-18 2003-04-22 Genome Therapeutics Corporation Nucleic acid and amino acid sequences relating to pseudomonas aeruginosa for diagnostics and therapeutics
MX343752B (es) 1998-05-01 2016-11-22 Novartis Vaccines & Diagnostics Inc Antigenos de neisseria meningitidis y composiciones que los contienen.
WO2000010599A2 (en) 1998-08-19 2000-03-02 North American Vaccine, Inc. IMMUNOGENIC β-PROPIONAMIDO-LINKED POLYSACCHARIDE PROTEIN CONJUGATE USEFUL AS A VACCINE PRODUCED USING AN N-ACRYLOYLATED POLYSACCHARIDE
EP1123403A1 (en) 1998-10-22 2001-08-16 The University Of Montana OMP85 PROTEINS OF $i(NEISSERIA GONORRHOEAE) AND $i(NEISSERIA MENINGITIDIS), COMPOSITIONS CONTAINING SAME AND METHODS OF USE THEREOF
GB9823978D0 (en) 1998-11-02 1998-12-30 Microbiological Res Authority Multicomponent meningococcal vaccine
AU1626199A (en) 1998-12-04 2000-06-26 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The A vi-repa conjugate vaccine for immunization against salmonella typhi
EP1162999B1 (en) 1999-03-19 2006-11-29 Glaxosmithkline Biologicals S.A. Vaccine against Streptococcus pneumoniae
CA2365914A1 (en) 1999-04-09 2000-10-19 Techlab, Inc. Recombinant clostridium toxin a protein carrier for polysaccharide conjugate vaccines
JP2003518363A (ja) 1999-04-30 2003-06-10 カイロン エセ．ピー．アー． 保存されたナイセリア抗原
GB9918319D0 (en) 1999-08-03 1999-10-06 Smithkline Beecham Biolog Vaccine composition
AU1917501A (en) 1999-11-12 2001-06-06 University Of Iowa Research Foundation, The Control of neisserial membrane synthesis
BR0015961A (pt) 1999-11-29 2003-06-10 Chiron Spa Antìgeno de neisseria de 85kda
NZ520466A (en) 2000-01-17 2003-09-26 Chiron S Outer membrane vesicle (OMV) vaccine comprising n. meningitidis serogroup B outer membrane proteins
JP2003523208A (ja) 2000-01-25 2003-08-05 ザ ユニバーシティ オブ クイーンズランド 髄膜炎菌表面抗原ＮｈｈＡの保存領域を含むタンパク質
ATE503837T1 (de) 2000-02-28 2011-04-15 Novartis Vaccines & Diagnostic Hybride expression neisserscher proteine
GB0007432D0 (en) 2000-03-27 2000-05-17 Microbiological Res Authority Proteins for use as carriers in conjugate vaccines
NO20002828D0 (no) 2000-06-02 2000-06-02 Statens Inst For Folkehelse Proteinholdig vaksine mot Neisseria meningtidis serogruppe samt fremgangsmÕte ved fremstilling derav
WO2002009643A2 (en) 2000-07-27 2002-02-07 Children's Hospital & Research Center At Oakland Vaccines for broad spectrum protection against diseases caused by neisseria meningitidis
GB0103170D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
EP1328543B1 (en) 2000-10-27 2009-08-12 Novartis Vaccines and Diagnostics S.r.l. Nucleic acids and proteins from streptococcus groups a & b
GB0103171D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
GB0103169D0 (en) 2001-02-08 2001-03-28 Smithkline Beecham Biolog Vaccine composition
US20030035806A1 (en) 2001-05-11 2003-02-20 D'ambra Anello J. Novel meningitis conjugate vaccine
GB0115176D0 (en) 2001-06-20 2001-08-15 Chiron Spa Capular polysaccharide solubilisation and combination vaccines
CN100350972C (zh) 2001-07-26 2007-11-28 启龙股份公司 含有铝佐剂和组氨酸的疫苗
GB0121591D0 (en) 2001-09-06 2001-10-24 Chiron Spa Hybrid and tandem expression of neisserial proteins
MX339524B (es) 2001-10-11 2016-05-30 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de enfermedad meningococica.
GB0130123D0 (en) 2001-12-17 2002-02-06 Microbiological Res Agency Outer membrane vesicle vaccine and its preparation
WO2003080678A1 (en) 2002-03-26 2003-10-02 Chiron Srl Modified saccharides having improved stability in water
DE20321889U1 (de) 2002-08-02 2012-03-12 Glaxosmithkline Biologicals S.A. Impfstoffzusammensetzung
GB0220194D0 (en) 2002-08-30 2002-10-09 Chiron Spa Improved vesicles
ATE492288T1 (de) 2002-10-11 2011-01-15 Novartis Vaccines & Diagnostic Polypeptidimpstoffe zum breiten schutz gegen hypervirulente meningokokken-linien
ATE466875T1 (de) 2002-11-15 2010-05-15 Novartis Vaccines & Diagnostic Unerwartete oberflächenproteine in neisseria meningitidis
GB0227346D0 (en) 2002-11-22 2002-12-31 Chiron Spa 741
MXPA05011110A (es) 2003-04-16 2006-01-24 Wyeth Corp Composiciones inmunogenicas novedosas para la prevencion y tratamiento de un padecimiento originado por meningococos.
GB0316560D0 (en) 2003-07-15 2003-08-20 Chiron Srl Vesicle filtration
GB0419408D0 (en) 2004-09-01 2004-10-06 Chiron Srl 741 chimeric polypeptides
GB0419627D0 (en) 2004-09-03 2004-10-06 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
GB0424092D0 (en) 2004-10-29 2004-12-01 Chiron Srl Immunogenic bacterial vesicles with outer membrane proteins
MX2007008785A (es) 2005-01-27 2008-02-15 Childrens Hosp & Res Ct Oak Vacunas de vesicula basadas en gna1870 para proteccion de amplio espectro contra padecimientos causados por neisseria meningitidis.
US8679770B2 (en) 2005-09-05 2014-03-25 Glaxo Smith Kline Biologicals S.A. Serum bactericidal assay for N. meningitidis specific antisera
GB0524066D0 (en) 2005-11-25 2006-01-04 Chiron Srl 741 ii
AR064642A1 (es) 2006-12-22 2009-04-15 Wyeth Corp Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
US9579372B2 (en) 2008-02-21 2017-02-28 Glaxosmithkline Biologicals Sa Meningococcal fHBP polypeptides
GB0819633D0 (en) 2008-10-25 2008-12-03 Isis Innovation Composition
GB0917003D0 (en) 2009-09-28 2009-11-11 Novartis Vaccines Inst For Global Health Srl Purification of bacterial vesicles
AU2010310985B2 (en) 2009-10-27 2014-11-06 Glaxosmithkline Biologicals S.A. Modified meningococcal fHBP polypeptides
US9567377B2 (en) 2010-03-10 2017-02-14 Glaxosmithkline Biologicals Sa Immunogenic composition
ES2661569T3 (es) 2010-03-30 2018-04-02 Children's Hospital & Research Center At Oakland Proteínas de unión al factor H (fHbp) con propiedades alteradas y métodos de uso de las mismas
GB201015132D0 (en) * 2010-09-10 2010-10-27 Univ Bristol Vaccine composition
EP2750702A4 (en) 2011-08-31 2015-03-04 Childrens Hosp & Res Ct Oak MANIPULATED SEQUENCES FOR THE EXPRESSION OF ANTIGENS IN NEISSERIA AND METHOD OF USE THEREOF
GB201120634D0 (en) 2011-11-30 2012-01-11 Univ Sheffield Adjuvant polypeptide
ES2654613T3 (es) 2012-02-02 2018-02-14 Glaxosmithkline Biologicals Sa Promotores para una expresión aumentada de proteínas en meningococos
MX351993B (es) 2012-03-09 2017-11-03 Pfizer Composiciones de neisseria meningitidis y metodos de las mismas.
CN104602704B (zh) 2012-06-14 2019-08-06 诺华股份有限公司 针对血清组x脑膜炎球菌的疫苗
GB201215005D0 (en) 2012-08-23 2012-10-10 Isis Innovation Stabilised meningitis vaccine
SG10201907875TA (en) 2014-02-28 2019-09-27 Glaxosmithkline Biologicals Sa Modified meningococcal fhbp polypeptides
EP2916512B1 (en) 2014-03-07 2016-08-24 Mitsubishi Electric R&D Centre Europe B.V. Method for classifying a TCP connection carrying HTTP traffic as a trusted or an untrusted TCP connection
AR102324A1 (es) * 2014-07-17 2017-02-22 Glaxosmithkline Biologicals Sa Polipéptidos fhbp (proteína de unión al factor h) meningocócicos modificados
CN106659776A (zh) 2014-07-17 2017-05-10 葛兰素史密丝克莱恩生物有限公司 脑膜炎球菌疫苗
JP7443260B2 (ja) 2018-06-21 2024-03-05 ビーエーエスエフ ソシエタス・ヨーロピア 安定剤としての３－フェニル－ベンゾフラン－２－オンジホスフェート誘導体

Also Published As

Publication number Publication date
US12415838B2 (en) 2025-09-16
ES2841378T3 (es) 2021-07-08
US11932671B2 (en) 2024-03-19
AU2018202431A1 (en) 2018-04-26
SG10201907875TA (en) 2019-09-27
BR112016019735A2 (pt) 2017-10-17
CA2940447C (en) 2023-07-11
EP3782643A1 (en) 2021-02-24
US20210253647A1 (en) 2021-08-19
EP3110442B1 (en) 2020-10-14
US20190315812A1 (en) 2019-10-17
PL3110442T3 (pl) 2021-04-19
MX373277B (es) 2020-05-20
HRP20202080T1 (hr) 2021-02-19
AU2015222121A1 (en) 2016-10-13
CN106661092B (zh) 2021-07-06
HUE052293T2 (hu) 2021-04-28
KR20160127104A (ko) 2016-11-02
RS61246B1 (sr) 2021-01-29
CN106661092A (zh) 2017-05-10
US11021522B2 (en) 2021-06-01
US10392424B2 (en) 2019-08-27
IL247125A0 (en) 2016-09-29
EA034954B1 (ru) 2020-04-10
JP2021019629A (ja) 2021-02-18
LT3110442T (lt) 2020-12-28
ZA201605534B (en) 2022-05-25
KR20230035455A (ko) 2023-03-13
SMT202000704T1 (it) 2021-01-05
KR102779223B1 (ko) 2025-03-07
EA201691429A1 (ru) 2017-02-28
JP6786394B2 (ja) 2020-11-18
JP7555785B2 (ja) 2024-09-25
CA2940447A1 (en) 2015-09-03
EP3110442A1 (en) 2017-01-04
IL247125B (en) 2021-12-01
DK3110442T3 (da) 2020-12-14
AU2015222121B2 (en) 2018-01-18
JP2017512060A (ja) 2017-05-18
SG11201606478YA (en) 2016-09-29
JP2022177111A (ja) 2022-11-30
US20170008933A1 (en) 2017-01-12
US20240218026A1 (en) 2024-07-04
MX2016011176A (es) 2017-02-23
MX2020004419A (es) 2020-07-29
CY1123622T1 (el) 2022-03-24
WO2015128480A1 (en) 2015-09-03

Similar Documents

Publication Publication Date Title
ZA201700170B (en) Modified meningococcal fhbp polypeptides
ZA201605534B (en) Modified meningococcal fhbp polypeptides
GB2528701B (en) Pillow
GB2536850B (en) Pillow
AU358659S (en) Blender
SG11201703111PA (en) Improved valve
ZA201701348B (en) New polypeptides
GB2522293B (en) Rotary valve
IL245343A0 (en) Carbon unit
EP3114968A4 (en) Height-adjustable pillow
TWI560099B (en) Stepper
PL2902575T3 (pl) System okuciowy
IL246533A0 (en) new proteins
PT3110442T (pt) Polipéptidos fhbp meningocócicos modificados
GB201400508D0 (en) Mutant polypeptides
AU358660S (en) Blender
GB201420332D0 (en) Power-bet blackjack
AP00957S1 (en) Blender
GB201419237D0 (en) Novel polypeptides
GB201403024D0 (en) Polypeptides
GB201410265D0 (en) Novel polypeptides
GB201410184D0 (en) Odontalgic preparation
GB201405913D0 (en) Rotary Controller
PH32014000868S1 (en) Hand blender
PL2899341T3 (pl) System okuciowy